Kornimate/medical-research-clean huggingface dataset:
ipilimumab administered to stage iiic stage iv melanoma after reg. t cell depletion with denileukin diftitox

Conditions: Metastatic Melanoma

Summary: this is an open-label, clinical efficacy study of ipilimumab in patients with stage iiic and stage iv melanoma who have recently been treated with denileukin diftitox. approximately 42 patients with radiographically measurable melanoma who have received at least one cycle of denileukin diftitox will be enrolled and treated in the study.

this is an open-label, clinical efficacy study of ipilimumab in patients with stage iiic and stage iv melanoma who have recently been treated with denileukin diftitox. approximately 42 patients with radiographically measurable melanoma who have received at least one cycle of denileukin diftitox will be enrolled and treated in the study.

Eligibility criteria:
inclusion criteria: 1. male or female patients ≥18 years of age; 2. patients with histological confirmed melanoma (stage iiic or stage iv, american joint commission on cancer); 3. eastern cooperative oncology group (ecog) performance status (ps) of 0 to 2; 4. life expectancy ≥3 months; 5. treatment with denileukin diftitox within 42 days prior to first dose of ipilimumab; 6. at least 1 site of radiographically measurable disease by immune-related response criteria (irrc); 7. adequate hematologic, renal, and liver function as defined by laboratory values performed within 42 days prior to initiation of dosing: * absolute neutrophil count (anc) ≥1.0 x 109/l; * platelet count ≥100 x 109/l; * hemoglobin ≥8 g/dl; * serum creatinine ≤3 x upper limit of normal (uln) * total serum bilirubin ≤2 x uln; * serum aspartate transaminase (ast/sgot) or serum alanine transaminase (alt/sgpt) ≤2x uln, and ≤3 x uln if liver metastases are present. 8. fertile males should use an effective method of contraception during treatment and for at least 3 months after completion of treatment, as directed by their physician; 9. pre-menopausal females and females \<2 years after the onset of menopause should have a negative pregnancy test at screening. pre-menopausal females must agree to use an acceptable method of birth control from the time of the negative pregnancy test up to 90 days after the last dose of study drug. females of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥1 year; 10. before study entry, written informed consent must be obtained from the patient prior to performing any study-related procedures. exclusion criteria: 1. prior treatment with ipilimumab; 2. known hypersensitivity to ipilimumab or any of its components; 3. steroids within one week prior to initiation of ipilimumab. 4. pre-existing autoimmune colitis. 5. patients with an allograft requiring immunosuppression; 6. known positive human immunodeficiency virus (hiv) 7. pregnant, breast-feeding, or refusing double barrier contraception, oral contraceptives, or avoidance of pregnancy measures; 8. have any other uncontrolled infection or medical condition that could interfere with the conduct of the study.
coenzyme q10 for gulf war illness: a replication study

Conditions: Gulf War Syndrome; Persian Gulf Syndrome; Mitochondrial Disorder, Respiratory Chain

Summary: the purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme q10) benefits symptoms, function, and quality of life in veterans with gulf war illness.


Eligibility criteria:
inclusion criteria: * meets both cdc and kansas deployment and symptom inclusion criteria. * does not have a disqualifying condition. * able to travel to a local quest facility for study blood draws. * adequate internet access to allow zoompro visit participation and remote survey completion. * health prior to the gulf war rated as "very good" or "excellent" (to exclude persons who may have had other health conditions with different mechanisms as the cause of their symptoms). * willing to defer initiation of discretionary treatments or supplements during the expected course of study participation. exclusion criteria: * participating in another clinical trial. * still-evolving adverse effects following another medication or health condition, such as covid or fluoroquinolone use. * on coumadin/ warfarin. * unable to participate for the required duration of the study.
a retrospective study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer

Conditions: Resectable Pancreatic Cancer

Summary: this trial is a retrospective, observational study, patients who underwent surgical resection of the pancreas for non-metastatic pancreatic cancer between 2016 and 2022 were selected and divided into two groups according to with (study arm) or without (control arm) nimotuzumab. the primary efficacy endpoint was overall survival (os).

this trial is a retrospective, observational study based on real-world data obtained from the health information system (his) of ruijin hospital, shanghai jiao tong university school of medicine. patients who underwent surgical resection of the pancreas for non-metastatic pancreatic cancer between 2016 and 2022 were selected and divided into two groups according to with (study arm) or without (control arm) nimotuzumab. the primary efficacy endpoint was overall survival (os).

Eligibility criteria:
inclusion criteria: * age≥18 years old, gender is not limited; * confirmed by histopathological or cytological diagnosis of pancreatic cancer; * underwent surgical resection of the pancreas for non-metastatic pancreatic cancer (including resectable/borderline resectable pancreatic cancer, or locally advanced pancreatic cancer); * received nimotuzumab plus adjuvant chemotherapy or adjuvant chemotherapy alone after surgery. exclusion criteria: * patients with other primary malignancies other than pancreatic cancer; * evidence of recurrence or distant metastasis before surgery * received immunotherapy drugs (such as pd-1 inhibitors, etc.) used during adjuvant therapy, or proprietary chinese medicines with anti-tumor indications, or hyperthermia, targeted therapy drugs other than nimotuzumab; * key information is missing (e.g., primary endpoint data were not available).
study of nasal airflow pressure optimization to resolve excessive snoring

Conditions: Snoring

Summary: this is a prospective, interventional, study in which patients with a history of habitual snoring to determine whether low pressure nasal continuous airway pressure can reduce the frequency, duration or intensity of snoring in subjects with mild to moderate snoring who do not have obstructive sleep apnea (osa).

in this a prospective, interventional, study, each patient will be studied four times. subjects without osa will undergo an initial observational control study to establish the presence of snoring (session 1); a single cpap titration night to determine the minimally effective cpap level (session 2) to alleviate snoring; a subsequent full night of cpap treatment at this cpap level (cpap not to exceed 6 cm h2o) using the cloud9™ low-pressure cpap device (session 3); and a final control night of study conducted off cpap to assess whether the patient's snoring remained stable over time (session 4). in this study, each subject shall serve as his/her own control.

Eligibility criteria:
inclusion criteria: * subject is \> 18 years of age. * subject is willing and able to provide written informed consent using a patient information and consent form that has been reviewed and approved by a governing institutional review board (irb). * subject has a history of habitual snoring (almost every night or every night for at least 30% of the night) as determined by the subject or a bed-partner. * subject has been pre-screened and demonstrates no excess daytime sleepiness on an epworth questionnaire (an assessment of daytime sleepiness; high number = greater sleepiness) score of less than 11, no history of witnessed apneas or nocturnal gasping/choking episodes and a body mass index (bmi) ≤ 35. inclusion criteria for treatment trials (nights 2 and 3): * subject meets inclusion criteria for the baseline trial (criteria a-d above) * the subject has snoring intensity that exceeds 40 dba during ≥30% of the respiratory efforts during sleep time on the baseline study night. exclusion criteria: * subject has been diagnosed with copd (chronic obstructive pulmonary disease), such as asthma, emphysema or chronic bronchitis. * subject has a history of heart disease, heart attack or stroke. * subject has uncontrolled or poorly controlled hypertension. * subject has been diagnosed with obstructive sleep apnea (osa), defined as an apnea hypopnea index (ahi) ≥ 5/hr in the presence of excessive sleepiness (an epworth score ≥ 11) or ahi ≥15/hr when there is no evidence of excessive daytime sleepiness (an epworth score ≤ 10). * subject is currently participating in another clinical study for which follow-up is ongoing.
randomized controlled trial of doxycycline to prevent acquisition of mycoplasma pneumoniae in an outbreak setting

Conditions: Mycoplasma Pneumoniae

Summary: this study was designed to determine whether taking daily doxycycline during an outbreak of mycoplasma pneumoniae could prevent a person from getting infected and interrupt ongoing disease transmission during an outbreak. doxycycline is a treatment for mycoplasma pneumoniae, but it is not certain that the drug could prevent disease if used prophylactically.


Eligibility criteria:
inclusion criteria: - working at hospital facility where outbreak of mycoplasma pneumoniae occured exclusion criteria: - pregnant, on antiseizure medications, allergic to macrolide antibiotics
suprachoroidal injection of triamcinolone acetonide with ivt aflibercept in subjects with macular edema following rvo

Conditions: Macular Edema; Retinal Vein Occlusion

Summary: a phase 2, multicenter, randomized, active-controlled, masked, parallel arm study designed to evaluate the safety and efficacy of a single suprachoroidal injection of cls-ta, triamcinolone acetonide injectable suspension, given along with an intravitreal (ivt) injection of aflibercept compared to ivt aflibercept alone in subjects with retinal vein occlusion (rvo).

a randomized, masked, controlled trial of safety and efficacy of suprachoroidal cls-ta in combination with intravitreal aflibercept in subjects with macular edema following retinal vein occlusion

Eligibility criteria:
inclusion criteria: * diagnosis of macular edema following rvo * history of me ≤ 12 months * 20-70 letters inclusive bcva using etdrs exclusion criteria: * has had an ivt injection of anti-vegf for rvo in the study eye * has had a corticosteroid injection in the past 3 months in the study eye * any uncontrolled ophthalmic condition in the study eye other than rvo

Keywords: rvo me central subfield thickness oct optical coherence tomography cystoid macular edema subretinal fluid eylea aflibercept anti-vegf
the effect of interscalene peripheral nerve block with 0.25% bupivacaine vs 0.125% bupivacaine on lung function

Conditions: Diaphragm Paralysis

Summary: peripheral nerve blocks are used to provide post-operative pain relief. nerve blocks in the neck, in the interscalene area, provide pain relief after shoulder surgery but can cause temporary weakness or paralysis of the diaphragm. the investigators hypothesized that a lower concentration of bupivacaine would cause less weakness of the diaphragm but still provide good pain relief. lung function and pain control was studied after interscalene peripheral nerve block with 20 milliliters of 0.25% bupivacaine or 0.125% bupivacaine.

prior to placement of interscalene brachial plexus peripheral nerve block (ispnb), diaphragm function was assessed using ultrasound as normal, no movement, or paradoxical. room air pulse oximetry (spo2) was recorded. patients were randomized to receive either 0.25% bupivacaine or 0.125% bupivacaine. ispnb was performed using a coded syringe of the study drug, so that the anesthesiologists performing the nerve block, the patient, and the nurses assessing the patient were blinded as to the concentration. patients were given a general endotracheal anesthesia for rotator cuff repair, and opioids were administered at the discretion of the attending anesthesiologist. when patients met criteria for pacu discharge, diaphragm function was again assessed using ultrasound and room air spo2 was recorded.

Eligibility criteria:
inclusion criteria: * patients presenting for outpatient rotator cuff repair * adults * english as the primary language exclusion criteria: * evidence of peripheral nerve damage on affected side * refusal of peripheral nerve block * pregnant women * lung disease, including obstructive sleep apnea * chronic opioid use * mental handicap

Keywords: bupivacaine concentration interscalene nerve block diaphragm function diaphragm weakness
pentoxifylline as an adjunct to citalopram in adult patients with major depressive disorder

Conditions: Major Depressive Disorder

Summary: the aim of this study is to test if combining the antidepressant citalopram with pentoxifylline (ptx), a medicine with anti-inflammatory and phosphodiesterase inhibitory properties, enhanced antidepressant efficacy in adult patients with major depressive disorder (mdd) when compared to citalopram alone.

according to mounting evidence, inflammation and phosphodiesterase (pde) pathways may play a role in the pathogenesis of psychiatric diseases such as mdd. ptx is a phosphodiesterase inhibitor and has anti-inflammatory and antioxidant effects. therefore, it has been hypothesized that mdd patients taking combined administration of the citalopram, a selective serotonin reuptake inhibitor (ssri), and ptx would show a higher improvement in depression symptoms. the relationship between the hamilton depression rating scale-17 items (ham-d-17) score and various biological markers and their potential role in the therapeutic outcome of mdd will be assessed.

Eligibility criteria:
inclusion criteria: * provide written, voluntary informed consent prior to study enrollment. * male or female between the ages of 21 to 65. * patient must be diagnosed with a moderate to a severe depressive episode, as determined by the madrs score \>21. * prior to taking part in the trial, all patients were requested to abstain from all psychotropic and anti-inflammatory medications for at least four weeks. exclusion criteria: * current psychotic symptoms or perceptual problems of any kind, at the discretion of the investigator * the presence of a contraindication to ptx, such as a drug allergy or xanthine derivative allergy * the presence of cardiovascular diseases, including high blood pressure, a recent myocardial infarction, cardiac arrhythmia, coronary artery disease, or a coagulation disorder * renal impairment, defined as creatinine clearance less than 80ml/min * patients who have previously received electroconvulsive therapy (ect) * patients who have inflammatory disorders * patients with a concurrent active medical condition * patients with a history of seizures * patients who are pregnant or nursing females. * patients with bipolar i or bipolar ii disorder * patients with personality disorders * patients with eating disorders * patients with substance dependence or abuse
augmented bladder neck reconstruction trial for improved urinary function after radical prostatectomy

Conditions: Prostate Cancer; Urinary Incontinence; Surgery

Summary: the investigators are conducting a prospective, randomized trial to investigate whether patients randomized to receive an augmented bladder neck reconstruction (abnr) at the time of robotic-assisted laparoscopic prostatectomy experience improved urinary function post-operatively compared to patients who undergo prostatectomy with a standard bnr. an abnr here consists of the autologous medial umbilical ligament sling as well as a bladder neck intussusception stitch. the standard bnr group will receive the intussusception stitch only.

a bladder neck reconstruction is a standard step in performing a radical prostatectomy. over the years, various maneuvers to improve continence have been tried and studied including intussusception stitches and slings. slings of various origins have been used by surgeons at the time of radical prostatectomy without consistent evidence demonstrating a benefit (vas deferens, biologic). however, use of the medial umbilical ligament to create a sling has not previously been studied in a randomized trial. the medial umbilical ligaments are normally cut during intraperitoneal robotic-assisted laparoscopic radical prostatectomy to allow the surgeon access to the retzius space between the bladder and pubic bone. to create a medial umbilical ligament autologous sling, the ligaments are dissected out and wrapped around the vesicourethral anastomosis. the investigators are conducting a prospective, randomized trial to investigate whether patients randomized to receive an augmented bladder neck reconstruction (abnr) at the time of robotic-assisted laparoscopic prostatectomy experience improved urinary function post-operatively compared to patients who undergo prostatectomy with a standard bnr. an abnr here consists of the autologous medial umbilical ligament sling as well as a bladder neck intussusception stitch. the standard bnr group will receive the intussusception stitch only.

Eligibility criteria:
inclusion criteria: * men aged 40 to 70 years of age with localized prostate cancer (clinical stage t2c or less, gleason grade 5+5=10 or less without any evidence of distant metastases) * scheduled to undergo curative robot-assisted radical prostatectomy exclusion criteria: * planned pre-operative or post-operative (within 1 month) androgen therapy * planned pre-operative or post-operative (within 1 month) radiation therapy * history of spinal trauma or surgery to the brain or spinal cord * pre-operative history of stress urinary incontinence
french observatory on hospitalizations in cardiology of patients of 80 years and over

Conditions: Cardiovascular Disease

Summary: because of increased life expectancy and improved therapeutic methods in cardiology, the proportion of very old patients with cardiovascular disease increases. however, clinical practice "in real life" are still insufficiently known in this population. the recommendations still lack of studies specifically devoted to elderly or very elderly, an extrapolation of data based on evidence obtained in younger populations. this is a multicenter observational study during a day. on this day, all participating centers fill a questionnaire for each patient 80 years or older hospitalized in their service.

information about the center will be collected: non-university or university center, presence of coronary angiography room, number of beds, number of patients 80 years or older hospitalized in the day of the investigation. the questionnaire is designed to: * know the history of cardiovascular and noncardiovascular patient and degree of dependence * know the reason for hospitalization * evaluate the diagnostic and therapeutic already implemented or planned for this patient the day of the survey, information on each patient 80 years or older hospitalized in the service will be collected: * patient data: date of birth, sex, status. the patient identification data (name, surname, address) will not be collected. * patient history: date of last hospitalization, life, cardiovascular risk factors, cardiovascular and non cardiovascular history, date of last hospitalization, life * circumstances of admission: course of care before admission, admission to intensive care unit or hospital unit classical primary diagnosis and diagnosis (s) partner (s) * initial assessment: treatment admission, major hemodynamic, electrocardiographic and biological * regarding the current hospitalization: diagnosis already implemented or planned (echocardiography, angiography, electrophysiological study, etc ...), therapeutic methods already implemented or planned angioplasty, percutaneous valve intervention, conventional or biventricular stimulation, cardiac surgery, medication * become of the patient after hospitalization * the clinician's subjective impressions about the condition of the patient and monitoring recommendations * assessment of addiction: adl scale no monitoring of patients is contemplated.

Eligibility criteria:
inclusion criteria: * patient aged 80 years or more * patient present in a cardiology service in the morning (8:00 to 12:00) the day of the survey * admission to the service took place on the survey day or in the 15 days preceding the survey. exclusion criteria: * patient with age \<80 years. * patient who have expressed a refusal to participate in the study

Keywords: older patients aged, 80 and over cardiology
dairy products, diabetes and genetics

Conditions: Insulin Sensitivity; Type2 Diabetes

Summary: this study will investigate the in-depth the benefits of dairy consumption on glucose metabolism in patients at risk of type 2 diabetes using novel genomics methodology.to do so, 33 individuals at risk of type 2 diabetes will be randomly subjected to an intervention study including a 6-week intensive dairy product consumption period and a 6-week dietary counselling period.

more than 9 million canadians are living with diabetes or prediabetes. type 2 diabetes is a disorder characterized by high blood glucose. dietary modification is a key component in type 2 diabetes management. for example, dairy product consumption has beneficial effects on metabolic health. yet, researchers have shown that mixed results exists for insulin sensitivity.

Eligibility criteria:
inclusion criteria: * caucasian men and postmenopausal women (absence of menstrual cycles for \>12 months) aged \>18 yrs; * bmi between 25-40 kg/m2; * hyperinsulinemia (fasting plasma insulin \>90 pmol/l); * fasting plasma glucose (fpg) \<7.0 mmol/l; hba1c \<6.5%); * if treated with lipid-lowering agents, the dose must have been stable over the last 3 months; * stable body weight (±5%) for 3 months; * willing to consume study foods and able to follow protocol and give informed consent. exclusion criteria: * failure to meet any one or more of the inclusion criteria; * diagnosis of type 2 diabetes; * high dairy consumption ( 2 servings/day or more); * major surgery in the 3 months prior to study onset; * smoking; * incompatibility with dairy consumption (allergy, intolerance or dislike); * inflammatory bowel disease or other gastrointestinal disorder influencing gastrointestinal motility or nutrient absorption; * medications known to affect lipid and glucose metabolism other than those used to treat hypertension or dyslipidemia; * diseases known to affect glucose metabolism.